Healthcare Professional Portal

Click here for prescribing information and adverse event reporting information (hosted externally).
Our Services
PI & AE

QUVIVIQ™▼ (daridorexant) Video Overview

Introduction to QUVIVIQ™

by Naressa Govender-Petrikaitis, product specialist speaking on behalf of Idorsia Pharmaceuticals UK

Promotional material from Idorsia Pharmaceuticals UK Ltd.

Discover how QUVIVIQ™ ▼ (daridorexant) is different to other hypnotics1,2:

Head icon illustrating that QUVIVIQ (daridorexant) works differently

Works differently1,2

50 mg tablet icon illustrating that QUVIVIQ (daridorexant) is taken differently

Is taken differently1,3

Sun icon illustrating that QUVIVIQ (daridorexant) is experienced differently

Is experienced differently1,4

Learn more
Learn more

Book an appointment

One of our product specialists would be happy to answer your questions.

QUVIVIQ™ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1

References

  1. QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
  2. Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
  3. NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated June 2024. Accessed July 2024.
  4. Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.

Prescribing information and adverse event reporting information can be accessed using the PI & AE button at the side.
This information is intended for UK healthcare professionals.

Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.

UK-DA-00388 | Date of preparation: August 2024

Copyright © 2026 Idorsia Pharmaceuticals Ltd
Create an account
Idorsia logo
Access our in-depth e-learning resources on chronic insomnia
Title *
First name *
Last name *
Professional email *
Password *
Specialty *
Professional registration number *

Select below to keep informed of further resources:

You already have an account? 

Sign in

Gain access to resources on chronic insomnia​

Register to get access to:

  • Insightful videos
  • Patient resources
  • E-Learning programme
  • And details about us and our offerings
Hands holding the 'How well do you sleep?' patient questionnaire, a conversation starter on chronic insomnia
Welcome back!
Idorsia logo

Please complete the form below to sign in.

You don’t have an account? 

Sign up

Table of Contents

Idorsia logo

You are now entering
pro.idorsia.uk

You are being redirected to our partner’s website pro.idorsia.uk.       The content of this website contains promotional information for UK healthcare professionals and is managed by
Idorsia Pharmaceuticals UK Ltd.

Enter website

UK-DA-01463 | Date of preparation: April 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Your resource is ready to download.

Providing your details is optional, but enables us to share future updates and resources that may be of interest to you.

Download will open in a new window.

Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.

Idorsia logo

You are now leaving
pro.idorsia.uk

You will now be redirected to an independent third party site that is maintained outside of this website, where all Idorsia Pharmaceuticals Ltd UK’s medicines can be found: the electronic Medicines Compendium (eMC)

Continue to medicines.org.uk

UK-DA-00439 | Date of preparation: February 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd
Idorsia logo

You are now leaving
pro.idorsia.uk

You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.

You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.

Cancel
Go to link

UK-DA-00445 | Date of preparation: Februrary 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd

Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.

It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.

For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.

Idorsia logo

Welcome to the Idorsia UK
Healthcare Professional Portal

This information is intended for UK Healthcare Professionals only.

By entering this site you are confirming that you are a UK Healthcare Professional.

I am a UK healthcare professional
I am a member of the public

UK-DA-00217 | Date of preparation: February 2026

Copyright ©2026 Idorsia Pharmaceuticals Ltd